Last Update 19 Jan 26

CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion

Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.
The limited adjustments to long term growth and P/E assumptions suggest confidence that CONMED can broadly stick to its current execution path without requiring a major reset of expectations.
Keeping the fair value unchanged while refining inputs signals that, in bullish analysts’ view, CONMED’s current valuation case still lines up with their base case outlook rather than needing a fresh rerating.
The small scale of the revisions is interpreted by some bullish analysts as a sign that recent information fits reasonably well with prior models, which can be reassuring for investors who value consistency in forecasts.

Bearish Takeaways

Bearish analysts may see the need to tweak growth and P/E assumptions, even slightly, as a reminder that CONMED’s longer term execution still carries uncertainty and that the path to the modeled fair value is not risk free.
The unchanged fair value of $48.40, despite refined inputs, can also be read as a signal that there is limited new evidence to justify a higher valuation right now, which may temper enthusiasm for aggressive multiple expansion.
Some cautious analysts could argue that relying on modestly lower discount rates to support the same fair value highlights sensitivity to macro and funding conditions, which might pressure valuation if those inputs shift again.
The incremental nature of the revisions might leave bearish analysts unconvinced that current assumptions fully reflect potential execution setbacks or changes in investor appetite for higher P/E medical device names.

What's in the News

CONMED plans to exit its gastroenterology product lines, aiming to align operations and resources with core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.
The company accelerated the end of its distribution agreement with W. L. Gore & Associates for the Gore VIABIL biliary stent to January 1, 2026, instead of after December 31, 2026, as previously indicated in its 10-Q filing.
Olympus, W. L. Gore & Associates and CONMED jointly announced that exclusive global distribution rights for the VIABIL device will transfer to Olympus, with U.S. distribution moving to Olympus from January 1, 2026 while CONMED continues support through December 31, 2025.
CONMED announced a share repurchase program authorizing up to US$150 million of common stock and separately disclosed that, from July 1, 2025 to September 30, 2025, it repurchased 6,123,353 shares in total under a prior buyback plan, equal to 21.23% of shares for US$162.54 million.
The Board suspended the quarterly cash dividend in connection with extending the share repurchase program and also provided several updates to earnings guidance for 2025, including revenue guidance of US$1.365b to US$1.372b for the full year and an estimated EPS impact of approximately US$0.07 from recent tariff announcements in the fourth quarter of 2025.

Valuation Changes

Fair Value: unchanged at US$48.40 per share, indicating no revision to the core valuation output.
Discount Rate: moved slightly from 9.22% to 9.17%, a small reduction in the rate applied to future cash flows.
Revenue Growth: effectively steady, with the model input remaining around 5.05%.
Net Profit Margin: effectively unchanged at about 10.80% in the updated assumptions.
Future P/E: adjusted marginally from 11.59x to 11.57x, reflecting a very small change in the valuation multiple used.

8 views

Key Takeaways

Strong positioning in minimally invasive and robotic-assisted surgery, along with regulatory trends and innovation, drives recurring revenue growth and expands long-term market opportunities.
Operational improvements and enhanced R&D investment are set to strengthen margins, earnings, and international sales while supporting sustained financial flexibility.
Ongoing supply chain, competitive, and macroeconomic challenges threaten CONMED's growth, profitability, and global expansion, while high expenses and reliance on capital budgets increase financial vulnerability.

Catalysts

About CONMED

A medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is poised to support durable procedure volume growth and increase recurring revenue, driving sustained top-line growth.
Global mandates and rising legislative momentum around operating room air quality (e.g., smoke evacuation laws across an expanding number of states and international geographies) are significantly expanding CONMED's addressable market for Buffalo Filter, underpinning double-digit growth in this product line and broadening the company's long-term revenue base.
The global aging population and increased healthcare spending, especially in emerging markets, are fueling greater demand for CONMED's minimally invasive solutions and supporting international sales growth-with continued market penetration in Asia-Pacific and Latin America acting as a meaningful revenue and earnings growth catalyst.
Ongoing operational improvements, particularly in resolving supply chain constraints and optimizing procurement and production, are set to unlock capacity, enable share recovery in orthopedics, and generate material cost efficiencies-likely yielding margin expansion and stronger earnings growth as these initiatives take effect.
Enhanced R&D investment supporting proprietary product innovation (e.g., next-gen BioBrace, PlumeSafe PX5), paired with a strengthened balance sheet and declining leverage, provides CONMED with both pricing power and financial flexibility, boosting the potential for sustained improvements in net margins and long-term earnings resilience.

CONMED Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming CONMED's revenue will grow by 5.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.3% today to 9.8% in 3 years time.
Analysts expect earnings to reach $154.0 million (and earnings per share of $4.68) by about September 2028, up from $110.2 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.7x on those 2028 earnings, up from 15.2x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.7x.
Analysts expect the number of shares outstanding to grow by 0.21% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.55%, as per the Simply Wall St company report.

CONMED Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent supply chain challenges, particularly in orthopedics, have resulted in lost market share and a slower recovery pace, which could lead to prolonged revenue underperformance and increased risk of further share loss, hampering long-term top-line growth.
Continued heavy reliance on hospital capital spending and elective procedures, which are susceptible to cycles in healthcare budgets and macroeconomic factors (such as interest rates and tightened capital expenditures), exposes CONMED's revenue and earnings to downside risk during periods of financial constraint.
Elevated SG&A and R&D expenses as a proportion of sales, coupled with the need for significant ongoing investment in operational transformation and new product innovation, may limit operating margin expansion if not matched by accelerated sales growth, impacting long-term net margin and earnings potential.
Intensifying industry competition-including from medtech giants and disruptive new entrants with robotics and digital surgery solutions-risks eroding CONMED's market share and could result in downward pricing pressure, threatening both revenue growth and profitability as core product relevance is challenged.
Exposure to geopolitical risks (such as new tariffs, regulatory changes, or global trade tensions) and currency headwinds continues to weigh on international sales and gross margins, potentially reducing earnings resilience and limiting long-term global revenue diversification.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $61.0 for CONMED based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $68.0, and the most bearish reporting a price target of just $57.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.6 billion, earnings will come to $154.0 million, and it would be trading on a PE ratio of 15.7x, assuming you use a discount rate of 8.6%.
Given the current share price of $53.98, the analyst price target of $61.0 is 11.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on CONMED?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare